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Since indirect comparisons were performed, recommended methods of accounting for differences in patient groups between trials were followed. In particular, these differences were adjusted for placebo rates when similar placebo strategies were used in different studies.
Results of the review
The proportions of patients responding in combination dose-finding trials (ACR20, ACR50 and ACR70 thresholds) were:
with etanercept, ACR20 66%, ACR50 42% and ACR70 19%; with adalimumab, ACR20 67%, ACR50 55% and ACR70 27%; with infliximab, ACR20 47%, ACR50 29% and ACR70 12%; and with DMARDs, ACR20, 37%, ACR50 13% and ACR70 0%.
The proportions of patients responding in combination dose-findings and radiographic trials with adalimumab were 57% for ACR20, 42% for ACR50 and 24% for ACR70.
The response rates in monotherapy trials (ACR20, ACR50 and ACR70 thresholds) were: with etanercept, 59% for ACR20, 40% for ACR50 and 15% for ACR70; and with adalimumab, 41% for ACR20, 19% for ACR50 and 12% for ACR70.
The withdrawal rate during 6 months was 0.08 with etanercept, 0.08 with adalimumab, 0.12 with infliximab and 0.27 with DMARDs.
The rate of mild adverse events during a 6-month periods was 0.29 with etanercept, 0.29 with adalimumab, 0.54 with infliximab and 0.34 with DMARDs.
The rate of moderate adverse events during a 6-month period was 0.16 with etanercept, 0.16 with adalimumab, 0.31 with infliximab and 0.34 with DMARDs.
The rate of severe adverse events during a 6-month period was 0.07 with etanercept, 0.07 with adalimumab, 0.1 with infliximab and 0.06 with DMARDs.
The initial value of the HAQ was 1.55 (standard deviation, SD=0.61).
The utility/HAQ regression gradient was 0.76 -0.28 HAQ.
The HAQ progression due to no response was 0.066 (range: 0.016 -0.066).
The HAQ progression: response to DMARD was 0.017 (SD=0.02).
The HAQ progression: response to biological agent was 0.017 (range: 0 -0.017).
The odds ratio for response decrease was 0.98 (SD=0.0045).
The relative risk of mortality due to RA was 1.63 (SD=0.14).
Measure of benefits used in the economic analysis
The summary benefit measure used was the quality-adjusted life-years (QALYs). These were estimated by combining utility values and expected survival, which were derived from the literature. An annual discount rate of 3% was applied. The authors pointed out that the results for adalimumab plus MTX were analysed twice. First, a comparison was made using similar studies of the TNF antagonists (DE009). Second, additional information from the larger adalimumab trial was used in a pooled analysis (DE009 and DE019).
Direct costs
The perspective adopted in the study was that of the third-party payer. The health services included in the economic evaluation were drugs, monitoring and drug administration, toxicity and hospitalisations. The unit costs were reported only for drugs, but extensive information on some categories of resources was provided. Resource use relating to drugs, monitoring and administration, and toxicity were estimated on the basis of experts' opinions. The consumption of hospital services was estimated using approximations based on patient HAQ-DI (Disability Index) scores. In particular, if a patient's HAQ-DI was estimated to have improved, the patient's corresponding health care costs were assumed to have decreased. Some costs were estimated from Swedish studies, but in general the source of the cost data was unclear. The total costs were calculated using a modelling approach. Discounting was relevant since lifetime costs were considered, and an annual discount rate of 3% was applied.
Statistical analysis of costs
The costs were treated deterministically in the base-case, but probabilistic distributions were assigned to all economic inputs in the probabilistic sensitivity analysis.
Indirect Costs
The indirect costs were not considered in the economic evaluation.
Currency
Euros (Euro).
Sensitivity analysis
A probabilistic sensitivity analysis was carried out to deal with the uncertainty around cost-effectiveness ratios. The model was run 1,000 times and probabilistic distributions were assigned to all model inputs. Further, a univariate sensitivity analysis was performed to determine the impact on the final cost-effectiveness estimates of individual parameters. Such parameters included rates of adverse events, direct costs, withdrawal rates, HAQ values, discounting (both costs and benefits), DMARD response rates, baseline age, mortality, and productivity losses. The alternative ranges of values were either derived from the literature or set by the authors.
Estimated benefits used in the economic analysis
Two analyses were performed. In the ACR50/DAS28 good analysis it was assumed that only ACR50 responders at 6 months would continue their treatment. In the ACR20/DAS28 moderate analysis it was assumed that responders to ACR20 would continue their treatment.
Using the ACR50/DAS28 good analysis, the estimated QALYs were: and assumptions were made so that a final common measure could be used in the current study. Moreover, some data came from selected groups of patients, which might not have been representative of a typical RA patient. Other model inputs were estimated from specific studies, the design and characteristics of which were not described in detail. The issue of uncertainty was satisfactorily addressed in the sensitivity analysis.
Validity of estimate of measure of benefit
The benefit measure used in the analysis was appropriate since QALYs capture the impact of the interventions on the most relevant dimensions of care (i.e. survival and quality of life). Further, QALYs are comparable with the benefits of other health care interventions. Discounting was applied as guidelines for economic evaluations suggest. Extensive information on the source of the utility weights and the approach used to calculate QALYs was provided.
Validity of estimate of costs
The perspective adopted in the study was that of the policy decision-makers. Only direct medical costs were included in the analysis. Details on resource consumption, in terms of drug doses and monitoring, were reported for most items but the information on other resources was limited. Further, the unit costs were not reported and this limits the possibility of replicating the cost analysis in other settings. Similarly, the sources of the data were not given for all items. Statistical analyses of the costs were not performed in the base-case, but probabilistic distributions were assigned to economic model inputs in the stochastic sensitivity analysis. The price year was reported, thus aiding reflation exercises in other time periods. The impact of indirect costs was investigated in the sensitivity analysis. The analysis showed that the inclusion of avoided productivity losses improved the cost-effectiveness of all biological treatments.
